StockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Buy

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

A number of other equities analysts have also weighed in on AUPH. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $9.37 on Friday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average price is $8.03 and its 200-day moving average price is $6.75. Aurinia Pharmaceuticals has a 52 week low of $4.71 and a 52 week high of $10.67. The stock has a market cap of $1.34 billion, a P/E ratio of -62.46 and a beta of 1.41.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise increased its stake in shares of Aurinia Pharmaceuticals by 126.6% in the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares in the last quarter. CWM LLC increased its stake in shares of Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 8,180 shares in the last quarter. FMR LLC increased its stake in shares of Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter worth $84,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 10,700 shares in the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.